Experimental COM902 drug shows promise in early cancer trial
NCT ID NCT04354246
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tested an experimental drug called COM902, alone or with other drugs, in 94 people with advanced cancers like ovarian, lung, and colon cancer. The main goal was to check safety and find the right dose. Researchers also looked for early signs that the drug might help control tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
COM902 (an experimental antibody) given alone or with COM701 and pembrolizumab
What this could lead to
If successful, this could point toward a new treatment option for people with advanced cancers that have not responded to standard therapies.
What could go wrong
This is an early Phase 1 trial with only 94 participants, so the main goal is safety, not effectiveness. The drug may not shrink tumors or may cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Florida Cancer Specialists
Sarasota, Florida, 34230, United States
-
Froedtert & Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
MD Anderson Cancer Center.
Houston, Texas, 77030, United States
-
Mary Crowley Cancer Research
Dallas, Texas, 75230, United States
-
Massachusetts General Hospital.
Boston, Massachusetts, 02114, United States
-
START Midwest.
Grand Rapids, Michigan, 49503, United States
-
The Ohio State University Comprehensive Cancer Center.
Columbus, Ohio, 43210, United States
-
The START Center for Cancer Care.
San Antonio, Texas, 78229, United States
-
The University of Tennessee WEST Cancer Center.
Memphis, Tennessee, 38138, United States